Podcasts about copd

Gina Hoots joins Cathy to explore where respiratory therapy meets health coaching, especially for people living with chronic lung conditions such as COPD, asthma, bronchiectasis, and more. With over 30 years' experience in both clinical and community settings, Gina shares how she combines science and compassion in her work. We dive into practical breathing techniques, the importance of proper inhaler use, integrating nutrition and lifestyle, and coaching strategies that empower clients beyond traditional medicine. The episode also highlights Gina's work with BluZone.Health, her leadership in respiratory care, and how health coaches and respiratory therapists can collaborate to improve outcomes. Expect both deeply technical takeaways and inspiring mindset shifts. In this episode, you'll discover: How Gina's dual roles as a respiratory therapist and health coach allow her to bridge gaps in patient education, care, and quality of life. Specific breathing practices (nose inhalation, lip‑pursed exhalation, huff coughs, etc.) that help reduce breathlessness, move mucus, and calm anxiety. How to assess if someone is on the “right” inhaler(s) vs. just using rescue inhalers, and what coaches should know about various inhaler classes. Ways health coaches can help clients being proactive in doctor visits—preparing questions, reviewing action plans, and improving collaboration. The role of nutrition, exercise, and reducing environmental/inflammatory exposures in lung health, not just “medication + oxygen.” The gaps in care Gina sees—where patients often don't get enough time, education, or follow‑up—and how health coaches and RTs can fill those gaps. Practical mindset shifts: turning directives into partnership, helping clients find personal “why,” and using breathing as a tool for anxiety and agency. Memorable Quotes: “If you have breathing problems, you're going to get an inhaler. Nobody tests for the breathing like they should.” “Many people think just with breathing problems, oxygen is the answer … But exercise can help that. Breath work … all of that really helps.” “The numbers don't really matter, but just the mindful breathing that you can control your breath.” Bio: Gina Hoots is a nationally recognized respiratory therapist and health coach with over 30 years of clinical and community experience, specializing in chronic lung conditions. As a Health Coach for BluZone.Health, Gina helps individuals live well with COPD, asthma, and other chronic respiratory illnesses through education, behavior change, and lifestyle optimization. She is the co‑creator and co‑host of The Cozy Lung Lounge Podcast, a compassionate, patient‑centered show offering real‑talk and resources for people with chronic lung disease and their caregivers. Whether it's unpacking new science or exploring the emotional side of illness, Gina's podcast makes space for the full experience of breathing and healing. Gina currently serves as the President of the Illinois Society for Respiratory Care, where she champions professional excellence and advocacy for the respiratory therapy field. She is also a COPD Foundation Captain, leading awareness efforts and community‑based support across Central and Southern Illinois. Rooted in both science and spirit, Gina is a proud member of the American Association for Respiratory Care and the Holistic Nurses Association, weaving a whole‑person approach into everything she does. From pulmonary testing labs to health coaching sessions, her mission is simple: to help people breathe easier and live more fully. Connect with Gina and explore her programs at hootenannyjoy.com. Mentioned in This Episode: Hootenanny Joy Recharge Your Day The Cozy Lung Lounge Podcast BluZone.Health Illinois Society for Respiratory Care COPD Foundation Asman Allergy Network Bronchiectasis & NTM Organization Links to Resources: Health Coach Group Website: thehealthcoachgroup.com Special Offer: Use code HCC50 to save $50 on the Health Coach Group website Leave a Review: If you enjoyed the podcast, please consider leaving a five-star rating or review on Apple Podcasts.

Revefenacin (brand name Yupelri) is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by blocking muscarinic receptors, particularly the M3 subtype, in airway smooth muscle. This antagonism reduces cholinergic bronchoconstriction and leads to sustained bronchodilation. Unlike short-acting anticholinergics such as ipratropium, revefenacin provides 24-hour bronchodilation with once-daily dosing. One of the distinguishing features of revefenacin is that it is the first nebulized LAMA approved for COPD maintenance therapy. Many patients with advanced COPD, physical limitations, or difficulty using handheld inhalers benefit from a nebulized formulation, as it allows medication delivery without requiring hand-breath coordination or a forceful inhalation. This makes it a useful option for patients with poor inhaler technique or those transitioning from hospital care. Pharmacokinetically, revefenacin is delivered via nebulization, with peak effects typically observed within a couple of hours. Importantly, systemic absorption is relatively low, but elderly patients or those with hepatic impairment may be more susceptible to anticholinergic side effects. Clinically, revefenacin improves lung function, reduces COPD symptoms, and can decrease exacerbation frequency. Common adverse effects include cough, dry mouth, constipation, and urinary retention. Caution is advised in patients with narrow-angle glaucoma or prostatic hyperplasia due to its antimuscarinic properties. Revefenacin is not intended for acute bronchospasm or rescue therapy—it is strictly for long-term, once-daily maintenance.

On today's Good Day Health Show - ON DEMAND…Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health.First up, Doug and Dr. Ken discuss the biggest news stories in the medical world, starting with a focus on new findings on COVID-19 silently accelerating the aging of arteries with a sharp in crease for women, updated guidance from the FDA on updated COVID-19 vaccines, and why the CDC and FDA aren't seeing eye-to-eye.Then, a discussion on Omega-3s and the difference between Omega-3, Omega-6 and Omega-9.Next up, the latest AI algorithm in a trial helps match potential volunteers to relevant medical trials in an effort to speed up the enrollment process and accelerate the pace of research to make it easier and faster to match patients with the proper studies.Doug gives an update on his hearing troubles with his left ear after having a lady bug stuck in his ear. This revelation leads to a discussion on hearing aids and the connection between hearing problems and early dementia/Alzheimer's.Then, a new non-opioid pain killer that offers relief without the risk of addiction.Lastly, Doug and Dr. Ken address listener questions, including the link between passive smoking and the risk of getting COPD. Are you ready for this? It appears that a father's exposure to passive smoking as a child may impair the lifelong lung function of this children, increasing their risk of developing COPD. Let that sink in.Another question addressed — “What happens if we skip breakfast later in life?” Turns out, this could lead to a higher likelihood of developing osteoporosis. Website: GoodDayHealthrShow.com Social Media: @GoodDayNetworks

The updated NICE guidance on asthma is ‘absolutely superb', advanced nurse practitioner Beverely (Bev) Bostock tells Dawn Liz Powell in this episode of the Clinical Update podcast. She explains that the guidance could help to improve asthma outcomes in the UK. ‘We're right at the top of the league for poor outcomes with asthma, and I suspect that that's about to change because we've finally taken on the approach that has been used in other countries,' Bev adds.She also talks about identifying occupational asthma, the diagnosis and management of COPD, the NHS lung cancer screening programme, and the need to keep the lungs clear of sputum in people with bronchiectasis.You can access the website version of this podcast, along with a list of key learning points, on MIMS Learning — and make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Educational objectivesAfter listening to this podcast, healthcare professionals should be better able to: Identify the triggers for occupational asthmaDiscuss the key recommendations of the 2024 update to the NICE asthma guidanceReview the different subcategories of COPD, according to the GOLD guidelinesUnderstand how the NHS lung cancer screening programme has led to incidental findings of emphysemaPlease note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.MIMS LearningSubscribe to MIMS LearningGuidance update: BTS/NICE/SIGN guidelines on diagnosis, monitoring and chronic asthma managementPodcast: Dr Cara Bossley on asthma in childrenCOPD pathology and diagnosisMIMSCombination inhalers for the treatment of asthma Hosted on Acast. See acast.com/privacy for more information.

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Host Dr. Riley Kirk is joined by Dr. Janice Makela, MD for part one of a two part episode; the conversation was so interesting they couldn't cut it short! They discuss the evolving landscape of cannabis medicine, particularly for the geriatric population. She emphasizes the importance of education for both patients and physicians, addressing common misconceptions and the need for responsible dosing. The discussion covers various consumption methods, including edibles and tinctures, and highlights the potential benefits and risks associated with cannabis use in older adults. Dr. Makela also shares insights on the importance of safe and legal access to cannabis products. The discussion delves into the risks associated with smoking, including bronchitis and COPD, and highlights the benefits of using vaporizers over traditional smoking methods. The speakers also discuss the efficacy of cannabis topicals for pain relief and their role in wound care, and the importance of considering drug interactions. The speakers advocate for a cautious approach to cannabis use, especially among older adults and those with existing health conditions. Please consult your physician or health care team for questions that relate specifically to your health. Find out more about Dr. Janice Makela, MD: https://www.janicemakelamd.com/ Want Exclusive Content and ad-free episodes? Join the Bioactive Patreon community for as little as $1/month to ask guests your burning questions, access exclusive content, and connect with Dr. Kirk one-on-one.⁠⁠⁠⁠⁠⁠⁠ www.Patreon.com/Cannabichem⁠⁠⁠⁠⁠⁠⁠

Fielding West has been a fixture of the Las Vegas comedy scene for over 50 years. But time has taken its toll and he now suffers from Emphysema, a form of COPD. But despite having to be strapped with an oxygen tank 24/7, Fielding has found a way to keep on his path of teaching people how to speak better on stage plus being part of the “Lance Burton and Friends” tour. He has even incorporated a way to make his audiences laugh with him at his malady. View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize View fullsize Fielding is like the Everyready bunny that just keeps going, and going, and going. He continues to make people laugh with his antics on stage and has even just been recognized by the International Magicians Society (IMS) with yet another Merlin Award. This episode was recorded in May 2025 and long before he knew he was going to be receiving this award. Download this podcast in an MP3 file by Clicking Here and then right click to save the file. You can also subscribe to the RSS feed by Clicking Here. You can download or listen to the podcast through Pandora and SiriusXM (formerly Stitcher) by Clicking Here or through FeedPress by Clicking Here or through Tunein.com by Clicking Here or through iHeart Radio by Clicking Here. If you have a Spotify account, then you can also hear us through that app, too. You can also listen through your Amazon Alexa and Google Home devices. Remember, you can download it through the iTunes store, too. See the preview page by Clicking Here. Enter for a Chance to Win a Copy of Castle Notes: Thoughts on the "Why" as well as the "How" by Steve Friedberg Enter with your name and email address. Hard copies will be shipped within the U.S. compliments of the author. PDF copies will go to those winners who reside outside the U.S. First Name Last Name Email Address Enter Today We respect your privacy. Your email will only be shared with the author. Thank you for entering the contest. If your name is randomly selected, then an email will be sent to you requesting your physical address where the book should be sent. Good luck!

Am 24. September ist der „Deutsche Lungentag“. Die Bronchiektasen-Erkrankung ist nach Asthma und COPD die häufigste chronische Erkrankung der Atemwege, von der in Deutschland etwa 100.000 Menschen betroffen sind. Trotzdem ist wenig über diese Erkrankung bekannt. Im Podcast spricht dazu die Lungen-Fachärztin Dr. Elena Terhalle.

We break down pneumothorax: risks, diagnosis, and management pearls. Hosts: Christopher Pham, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Pneumothorax.mp3 Download Leave a Comment Tags: Chest Trauma, Pulmonary, Trauma Show Notes Risk Factors for Pneumothorax Secondary pneumothorax Trauma: rib fractures, blunt chest trauma (as in the case). Iatrogenic: central line placement, thoracentesis, pleural procedures. Primary spontaneous pneumothorax Young, tall, thin males (10–30 years). Connective tissue disorders: Marfan, Ehlers-Danlos. Underlying lung disease: COPD with bullae, interstitial lung disease, CF, TB, malignancy. Technically, anyone is at risk. Symptoms & Differential Diagnosis Typical PTX presentation: Dyspnea, chest pain, pleuritic discomfort. Exam clues: unilateral decreased breath sounds, focal tenderness/crepitus. Red flags (suggest tension PTX): JVD Tracheal deviation Hypotension, shock physiology Severe tachycardia, hypoxia Differential diagnoses: Pulmonary: asthma, COPD, pneumonia, pulmonary edema (SCAPE), ILD, infections. Cardiac: ACS, CHF, pericarditis. PE and other acute causes of dyspnea. Diagnostics Bloodwork: limited role, except type & screen if intervention likely. EKG: reasonable given chest pain/shortness of breath.

Mary Iannelli sits down with former TPJ alum, James Lynch to see what it's like to take on an iconic role off broadway and then take it on the road as part of a national touring company.Credits:Audio Engineer Gary GlorOne Heartbeat Away is provided to The Theater Project by Gail Lou References:Saw, The Musicalhttps://www.sawthemusical.com/Backstagehttps://www.backstage.com/Zicam Nasal Swabshttps://www.zicam.com/our-products/cold-shortening/nasal-swabsNeti PotA neti pot is a device used for nasal irrigation, typically to flush out mucus and allergens from the nasal passages. It's a teapot-like container with a long spout, allowing you to pour a saline solution into one nostril, which then flows out the other. This process helps relieve symptoms of allergies, colds, and sinus congestion.Portable NebulizerA portable nebulizer is a compact, handheld medical device that converts liquid medication into a fine mist for inhalation, making it convenient for on-the-go use or travel. It offers a discreet and quiet way to deliver medication directly to the lungs, which is helpful for individuals with respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD).Vocal ResonanceVocal resonance is the process of amplifying and enriching the sound of your voice by using the resonating cavities in your head and throat. It's like an echo, where the sound waves bounce off reflective surfaces and enhance the sound's quality and projection. Think of it as the way your voice sounds full, rich, and carries well.

"Can early detection and community support improve COPD care?" In the final part of this episode, Dr. Olli Tikkanen speaks with David Mannino, MD, Jonnie Korinko, and Phyllis DiLorenzo about the critical role of early diagnosis, effective treatment, and community support for COPD patients. Mannino, MD discusses the latest research efforts to detect COPD in its early stages, before symptoms worsen. Jonnie Korinko emphasizes the importance of pulmonary rehabilitation programs, not only for physical activity but also for medication education and patient empowerment. Phyllis DiLorenzo shares her own experiences, highlighting the vital support networks available to COPD patients and how peer connections have made a meaningful impact on her journey. The guests also explore the challenges of reimbursement and access to pulmonary rehab, stressing the need for broader support and awareness to improve COPD care. This episode provides an in-depth look at the essential components of COPD management and offers valuable insights for anyone interested in respiratory health and patient advocacy. ___________________   This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behavior and Physical Activity Research with Less Hassle --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS. --- SB and PA measurements, analysis, and feedback made easy - Learn more about Fibion Research. --- Learn more about Fibion Sleep and Fibion Circadian Rhythm Solutions. --- Fibion Kids - Activity tracking designed for children. --- Explore our Wearables,  Experience sampling method (ESM), Sleep,  Heart rate variability (HRV), Sedentary Behavior and Physical Activity article collections for insights on related articles. --- Refer to our article "Physical Activity and Sedentary Behavior Measurements" for an exploration of active and sedentary lifestyle assessment methods. --- Learn about actigraphy in our guide: Exploring Actigraphy in Scientific Research: A Comprehensive Guide. --- Gain foundational ESM insights with "Introduction to Experience Sampling Method (ESM)" for a comprehensive overview. --- Explore accelerometer use in health research with our article "Measuring Physical Activity and Sedentary Behavior with Accelerometers ". --- For an introduction to the fundamental aspects of HRV, consider revisiting our Ultimate Guide to Heart Rate Variability. --- Follow the podcast on Twitter https://twitter.com/PA_Researcher  Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen  Follow Fibion on Twitter https://twitter.com/fibion  Check us on YouTube: https://www.youtube.com/@PA_Researcher 

"How can virtual rehab bring physical activity to more COPD patients?" In this second part of the episode, Dr. Olli Tikkanen speaks with David Mannino, MD, respiratory therapist Jonnie Korinko, and COPD patient advocate Phyllis DiLorenzo to explore the benefits and challenges of virtual pulmonary rehabilitation. Mannino, MD discusses the accessibility issues many COPD patients face with in-person rehab programs and how virtual options can bridge the gap. Jonnie Korinko emphasizes the importance of flexibility in treatment, as virtual programs allow patients in rural areas to engage in physical activity without traveling long distances. Phyllis DiLorenzo shares her positive experiences with virtual rehab, highlighting the community and support she's found through online programs and peer connections. The discussion also covers the importance of medication adherence, peer support, and how digital tools can help COPD patients maintain their exercise routines outside of formal rehab programs. The episode provides valuable insights for those interested in the future of telemedicine and how virtual pulmonary rehabilitation can enhance the quality of life for COPD patients. ______________   This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behavior and Physical Activity Research with Less Hassle --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS. --- SB and PA measurements, analysis, and feedback made easy - Learn more about Fibion Research. --- Learn more about Fibion Sleep and Fibion Circadian Rhythm Solutions. --- Fibion Kids - Activity tracking designed for children. --- Explore our Wearables,  Experience sampling method (ESM), Sleep,  Heart rate variability (HRV), Sedentary Behavior and Physical Activity article collections for insights on related articles. --- Refer to our article "Physical Activity and Sedentary Behavior Measurements" for an exploration of active and sedentary lifestyle assessment methods. --- Learn about actigraphy in our guide: Exploring Actigraphy in Scientific Research: A Comprehensive Guide. --- Gain foundational ESM insights with "Introduction to Experience Sampling Method (ESM)" for a comprehensive overview. --- Explore accelerometer use in health research with our article "Measuring Physical Activity and Sedentary Behavior with Accelerometers ". --- For an introduction to the fundamental aspects of HRV, consider revisiting our Ultimate Guide to Heart Rate Variability. --- Follow the podcast on Twitter https://twitter.com/PA_Researcher  Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen  Follow Fibion on Twitter https://twitter.com/fibion  Check us on YouTube: https://www.youtube.com/@PA_Researcher 

M. Bradley Drummond, MD, discusses how new inhaler technologies can detect early warning signs of COPD exacerbations.Let us know what you thought of this week's episode on Twitter: @physicianswkly Want to share your medical expertise, research, or unique experience in medicine on the PW podcast? Email us at editorial@physweekly.com! Thanks for listening!

"Can physical activity really improve the quality of life for COPD patients?" In this engaging first part of the episode, Dr. Olli Tikkanen speaks with David Mannino, MD, Jonnie Korinko, and Phyllis DiLorenzo to discuss the role of physical activity in managing Chronic Obstructive Pulmonary Disease (COPD). Mannino, MD explains the physical challenges that COPD patients face, particularly the downward spiral of reduced activity and muscle loss due to difficulty breathing. Jonnie Korinko, a respiratory therapist, shares insights on the benefits of pulmonary rehabilitation and the impact of structured exercise programs on patient outcomes. Phyllis DiLorenzo offers her personal perspective on living with COPD, highlighting how physical activity has played a critical role in managing her symptoms and improving her overall well-being. The conversation covers the physiological and psychological benefits of staying active, even with COPD, and the importance of building individualized exercise programs. The guests also discuss practical tips for incorporating physical activity into daily life, emphasizing that even small steps can make a difference. This episode provides valuable insights into how physical activity can be a powerful tool in improving the quality of life for those with COPD. _____________________ This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behavior and Physical Activity Research with Less Hassle --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS. --- SB and PA measurements, analysis, and feedback made easy - Learn more about Fibion Research. --- Learn more about Fibion Sleep and Fibion Circadian Rhythm Solutions. --- Fibion Kids - Activity tracking designed for children. --- Explore our Wearables,  Experience sampling method (ESM), Sleep,  Heart rate variability (HRV), Sedentary Behavior and Physical Activity article collections for insights on related articles. --- Refer to our article "Physical Activity and Sedentary Behavior Measurements" for an exploration of active and sedentary lifestyle assessment methods. --- Learn about actigraphy in our guide: Exploring Actigraphy in Scientific Research: A Comprehensive Guide. --- Gain foundational ESM insights with "Introduction to Experience Sampling Method (ESM)" for a comprehensive overview. --- Explore accelerometer use in health research with our article "Measuring Physical Activity and Sedentary Behavior with Accelerometers ". --- For an introduction to the fundamental aspects of HRV, consider revisiting our Ultimate Guide to Heart Rate Variability. --- Follow the podcast on Twitter https://twitter.com/PA_Researcher  Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen  Follow Fibion on Twitter https://twitter.com/fibion  Check us on YouTube: https://www.youtube.com/@PA_Researcher 

Happy Rātu e hoa mā! Today on the show, Rosetta and Milly chat to Johanna Cosgrove about her upcoming comedy shows at Goblin, and the duo chat with Roan Zaied about her research in COPD detection technology for Ready Steady Learn. Also, plenty of yarns about failing subjects in school for The Beths AOTW giveaway! Whakarongo mai nei!

Today on Ready Steady Learn, Roan Zaedi speaks with Rosetta and Milly about her research on ways to improve early detection of COPD (chronic obstructive pulmonary disease)—a serious lung disease that is the fourth leading cause of death worldwide. Roan's research focuses on using machine learning - a form of artificial intelligence (AI) that learns patterns from data - to personalise health profiles to predict who might be at risk from COPD. Whakarongo mai nei! Thanks to the University of Auckland!

In this Healthed lecture, Professor Hubertus Jersmann will explain, spirometry, as done in general practice, enables accurate and early detection of COPD, and could be utilised more often to identify the many people who have this condition but remain undiagnosed or misdiagnosed. In addition, he will present the practical considerations of performing spirometry in the primary care setting - the logistics, the contraindications, the interpretation of results as well as common pitfalls and challenges. This educational activity was developed by Healthed at the request of and with funding from GSK.See omnystudio.com/listener for privacy information.

This week on Family Flowers Only , I sit down with Helen Groarke . Helen speaks so openly about the devastating loss of her mum Ada to COPD, a woman she described as her best friend. Just two weeks later, her dad Phelim who had lived with bipolar all his life attempted to take his own life. Helen also shares the challenges that followed, from her son being diagnosed with an autoimmune condition to experiencing miscarriage. Through it all, she has carried immense strength, honesty, and love. Thank you to this episodes supporters Feeling stuck in your body? Grief can weigh heavily on us physically as well as emotionally. If you’re ready to try gentle movement from home Ecofitness by Korina Duffy is offering listeners a 30-day free trial. Move at your own pace, in your own space, even in your pyjamas. 💚 Sign up here: ⁠⁠⁠https://coach.everfit.io/package/QJ743362⁠⁠⁠ 🎙️ This episode was brought to you and recorded at GK Media Studio. They also offer a beautiful Legacy Package where you can record your own personal or family podcast, capture memories with a loved one, or tell your story in your own words.They can even travel to you. 📼 Learn more here: ⁠⁠⁠https://www.gkmedia.ie/legacy⁠⁠⁠ For more information on Grief Retreats visit ⁠⁠⁠www.griefireland.com⁠⁠⁠

BUFFALO, NY — August 14, 2025 — A new #research paper was #published in Volume 17, Issue 7, of Aging (Aging-US) on July 3, 2025, titled “Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort.” In this study, led by first author Eleanor Kate Phillips from Brigham and Women's Hospital and corresponding author Dawn L. DeMeo from Brigham and Women's Hospital and Harvard Medical School, researchers investigated how frailty impacts lung health and survival in individuals with a history of cigarette smoking. They found that frailty raises the risk of lung attacks and death, even in smokers with preserved lung function. This result shows why all current and former smokers should be checked for frailty. Frailty is a condition that makes the body more vulnerable to illness, especially in older adults. This study focused on more than 2,600 adults with a history of heavy smoking, many of whom showed no signs of lung damage on standard tests. At the second follow-up visit, participants were categorized as robust, prefrail, or frail and followed for about three years. Researchers tracked how often they experienced respiratory attacks, such as episodes of severe coughing or breathlessness, and whether they survived during that period. “COPDGene is a cohort study of individuals aged 45–80 with a minimum 10 pack-year smoking history.” The results showed that people who were frail had a three- to five-fold higher chance of developing serious or frequent respiratory attacks compared to those who were robust. These risks were not limited to people with chronic lung disease. In fact, many frail participants with normal lung function still faced a significantly higher chance of lung attacks and death. Even those in the “prefrail” stage, a milder form of frailty, were more likely to experience health complications. The research team also found that frailty was associated with an accelerated pace of biological aging, measured using a DNA-based test called DunedinPACE. This supports the idea that frailty may reflect deeper biological changes in the body that go beyond what traditional lung function tests can detect. These findings challenge the idea that standard lung tests can rule out future respiratory complications in people with a history of smoking. Altogether, the study shows that simple frailty checks could help identify early health problems, allowing for timely interventions that may prevent hospitalizations and potentially save lives. The study suggests that frailty screening may be a valuable tool in public health efforts to reduce respiratory disease and improve outcomes for aging adults. DOI - https://doi.org/10.18632/aging.206275 Corresponding author - Dawn L. DeMeo - redld@channing.harvard.edu Video short - https://www.youtube.com/watch?v=G1XQhQN6PQ8 Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206275 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, frailty, cigarette smoking, respiratory exacerbations, COPD, epigenetic aging To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠COPD Exacerbation⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Pulmonary section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Top 5 Topics:- Dental Sedation Gone Wrong- Malpractice vs. State Board: Which Destroys a Dentist's Career?- COPD, Sedatives, and a Near-Death Experience in the Dental Chair- The Shocking Truth About Untrained Dental Assistants and Sedation- Why One Dentist Was Banned From Practicing for 6 MonthsQuotes & Wisdom:"You can't just look at these medications—even nitrous—as candy. These are drugs. They have side effects. They need to be closely monitored." – Dr. Leffler (29:00)"The worst thing is a board complaint. I'd much rather a client be sued for malpractice than have a board action against them." – Dr. Leffler (25:00)"You don't pick your judges. These people were effectively functioning as judges, and you have to live with their decisions." – Dr. Leffler (23:45)"He had no vitals, no pulse ox, no blood pressure, no baseline readings—and he was sedated. That's incredibly risky." – Brendan (07:06)"The ADA guideline implies every patient needs a BP reading before every procedure. Otherwise, how do you know they're safe?" – Dr. Leffler (30:25)Questions:"Do we know which benzodiazepine was used?" — (01:31)"Would you have considered administering Flumazenil in the office?" — (09:03)"How do you give oral sedatives before the patient even gets to the office safely?" — (26:43)"Have you seen differences between states and how their boards respond to such cases?" — (17:45)"Could you give examples of states that are generally stricter or more lenient?" — (18:52)"What were the main points that the dental board used to sanction this provider?" — (26:17)Now available on:- Dr. Gallagher's Podcast & YouTube Channel- Dose of Dental Podcast #163- 7.2025This episode is a partnership with MedPro Group.#podcast #dentalpodcast #doctorgallagherpodcast #doctorgallagherspodcast #doctor #dentist #dentistry #oralsurgery #dental #dentalschool #dentalstudent #doctorlife #dentistlife #oralsurgeon #doctorgallagher

Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry data. Watch our featured guest's full episodes: GSK's Dheepa Chari on the evolving sphere of scientific communication Yacin Marzouki on disrupting the traditional omnichannel model BMS' Anita Gandhi on a decade of change in hematology Pfizer's Richard Maughan on the future of access in the UK GSK's Matt Mortimer-Ryan on behaviour-led pharma marketing Chiesi's Shish Patel on COPD, the climate and improving care AbbVie's Dr Daejin Abidoye on community and compassion in cancer care Bayer's Dr Joana Reis on the promise of AI in breast cancer

What happens when a physics graduate from the projects decides to return to professional boxing at age 40 after a nine-year hiatus? Ed Latimore's story defies every expectation you might have about both academic achievement and athletic excellence.In this candid conversation, Latimore shares the brutal realities behind his comeback fight, the hidden health issues that were sabotaging his performance for years, and the scientific approach he used to optimize his body at an age when most athletes have long retired. From discovering his thyroid was working against him to uncovering respiratory problems that mimicked COPD, his journey illustrates how even the healthiest among us can have invisible barriers to peak performance.But this isn't just a boxing story. Latimore articulates a philosophy that cuts straight to the heart of human limitation and choice. His insights about sacrifice, priority, and the mathematics of achievement apply whether you're trying to lose weight, build a business, or simply live with more intention.The conversation weaves through his upcoming memoir "Hard Lessons from the Hurt Business," his transition from fighter to writer, and the biomechanical insights he gained that revolutionized his understanding of athletic performance. Along the way, he demonstrates why sometimes the most efficient path isn't the best path for creation, and how constraints can become the foundation for extraordinary achievement.This is raw storytelling from someone who has lived at the intersection of intellectual rigor and physical combat, offering perspectives that challenge conventional wisdom about aging, health optimization, and what's actually possible when you refuse to accept limitations as permanent.BIG IDEAYou can have anything you want, you just can't have everything you want.Contact Info: Ed LatimoreTwitter:https://x.com/EdLatimoreInstagram: https://instagram.com/edlatimoreLinkedin: https://www.linkedin.com/in/edlatimore/YouTube: https://www.youtube.com/@EdLatimore1Website: https://edlatimore.comInvitee Email: edward.latimore@gmail.comSend Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

This week on “Talk About Las Vegas With Ira,” Ira welcomes award-winning magician and showbiz veteran Fielding West, fresh from being honored at the inaugural Global Magicians Hall of Fame ceremony in Las Vegas. In this revealing and entertaining conversation, Fielding shares how his magical journey began at the age of nine—sparked by a life-changing gift from his grandfather to help him overcome learning disabilities. That spark eventually led to a bold decision: dropping out of graduate school after a chance encounter with none other than Steve Martin. After driving the comedy icon to a gig and watching him perform, Fielding knew his true calling was on stage, not in a classroom. Fielding dives into the art of misdirection, the thrill of discovering magic's secrets, and the pure joy of an audience's reaction. He shares the hilarious origin of his unique sense of humor—including a childhood prank involving a whoopee cushion—and talks candidly about performing today while managing COPD with an oxygen concentrator, calling it the “bullet catch” for aging magicians. He also reflects on the legendary “magician's graveyard,” names his top three magicians in history, and offers heartfelt insights into his decades-long friendship with master magi-cian Lance Burton. It's a magical, moving, and memorable episode you won't want to miss. (Also Watch Full Podcast Video)

Morning Prayer (people with asthma and COPD  #asthma #copd #prayer #prayers #jesus #god #morningprayer #aimingforjesus #holyspirit Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

Your lungs work around the clock to bring oxygen to every cell in your body. But air pollution, allergens, infections, and stress can take a toll on respiratory function over time. The good news? Nature offers powerful nutrients that help protect, nourish, and strengthen lung tissue.In this episode George discusses COPD and the 5 nutriens to help support lung healthMedical contributor Dr. Jeff Crippen discusses the link between Zinc deficiency and Cancer www.crippenwellness.com

Michele R. Schaeffer, PhD, Andreas von Leupoldt, PhD, and Daniel Langer, PhD, join CHEST® Journal Podcast Moderator, Alice Gallo De Moraes, MD, FCCP, to discuss their research into inhaled menthol as a potential treatment for dyspnea relief during cycle exercise for patients with COPD.  DOI: 10.1016/j.chest.2025.03.002 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

Dr. John Granton, a critical care and transplant physician at Toronto General Hospital, shares his journey in pulmonary hypertension and lung transplantation, detailing the groundbreaking advancements in transplant technology. He discusses the evolution of lung preservation methods, the challenges of chronic rejection, and the hope for longer-lasting transplants. With a passion for improving patient outcomes, Dr. Granton envisions a future where transplant becomes obsolete—replaced by treatments that cure underlying diseases. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. @UHN @teamphhope #phawareMD #PHILD #transplant @phacanada

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.

Top 7 Underrated Supplements Top 7 Underrated Supplements. (1:11) #1 - Vitamin D. (50%) take 2000-4000iu. (2:01) #2 - Vitamin k2. (97%) 100micrograms a day. (8:48) #3 - NAC. 600-1800mgs a day. (11:52) #4 - Berberine. 500mgs 3x day w/food. (13:23) #5 - Glycine. Take before bed on an empty stomach. (15:34) #6 - Choline. 500-2000mgs a day. (17:04) #7 - Grape seed extract. 100-300mgs daily. (21:18) Related Links/Products Mentioned Visit MASSZYMES by biOptimizers for an exclusive offer for Mind Pump listeners! **Code MINDPUMP10 at checkout for 10% off any order. ** July Special: MAPS Split or Anabolic Metabolism Bundle 50% off! ** Code JULY50 at checkout ** Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data Effect of vitamin D supplementation on muscle strength, gait and balance in older adults: a systematic review and meta-analysis Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials Impact of vitamin D supplementation on C-reactive protein; a systematic review and meta-analysis of randomized controlled trials 97% of Americans are Low In Vitamin K2 Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis Mind Pump #2060: Maximize Fat Loss With Continuous Glucose Monitors: Kara Collier Efficacy of Berberine in Patients with Type 2 Diabetes - PMC The Effects of Glycine on Subjective Daytime Performance in Partially Sleep-Restricted Healthy Volunteers 6 Warning Signs of Choline Deficiency You Must Watch For The impact of grape seed extract treatment on blood pressure changes Visit Legion Athletics for the exclusive offer for Mind Pump listeners! ** Code MINDPUMP for 20% off your first order (new customers) and double rewards points for existing customers. ** Mind Pump Podcast – YouTube Mind Pump Free Resources  

Indianapolis is one of the hotbeds of Histoplasmosis, which is often misdiagnosed and can lead to other health issues throughout the body.  In this episode, you'll learn:—What Histoplasmosis is and the symptoms of it, which "seems like the flu when you get it".  And how "a lot of doctors aren't even aware of it".—The story of how Dr. Prather's own father suffered from COPD as a result of an underlying Histoplasmosis infection he contracted as a kid by being in charge of the chicken coop.—The difficulty in accurately testing for Histoplasmosis, which can be misdiagnosed as Tuberculosis, Lyme Disease, Sarcoidosis, or Macular Degeneration.  And how Histoplasmosis is "the number one cause of blindness in Indiana".—How Antibiotics and Steroids that are often prescribed by doctors will actually make the Histoplasmosis "take off" and become "systemic".—Why Indianapolis is such a center for Histoplasmosis outbreaks.  And why Dr. Prather says that everyone who has lived in the area for 5 years has Histoplasmosis.—The natural products Dr. Prather has found to be even more effective for Histoplasmosis than prescription drugs because they actually rebuild the body's immune system.  And why Dr. Prather says "the strongest anti-fungal medicine known to man" is Oregano Oil.—The importance of Homeopathy, which Dr. Prather says has made a big difference in "the real serious cases" of Histoplasmosis.  And why Dr. Prather says "you are going to have problems" if your Vitamin D and Vitamin A are low. —How a weakened immune system, nutritional deficiency, or stress are usually the reasons that a Histoplasmosis infection takes off in the first place.  And how you probably have a secondary Histoplasmosis infection that needs to be addressed if you live in Indianapolis and have Long COVID.—Why Chiropractic, Acupuncture, and Diathermy are helpful for Histoplasmosis.  And the Spleen-21 Acupuncture point that causes people to feel immediately better when they are sick.—How Dr. Prather has had patients suffering from Kidney failure and patients dealing with Hypertension whose real underlying issue was Histoplasmosis.http://www.TheVoiceOfHealthRadio.com

Story at-a-glance Chronic respiratory diseases remain profitable but poorly treated, subjecting patients to expensive healthcare, impaired stamina, and painful decline DMSO is an "umbrella remedy" treating diverse ailments through therapeutic properties including reducing inflammation, improving circulation, and reviving dying cells These properties uniquely address underlying causes of chronic respiratory diseases by reducing fibrosis and inflammation, restoring damaged organs, and improving circulation DMSO addresses respiratory infections through antimicrobial activity, reduced lung inflammation, and potentiation of antimicrobial therapies Extensive published data and user reports demonstrate DMSO's remarkable results for asthma, COPD, cystic fibrosis, interstitial lung disease, pulmonary fibrosis, and pneumonia, including cases in which transplant was no longer necessary due to significant organ recovery

Send Audrey a Text to get your question answered on the showAs requested, here is the episode on Heaves, also known as RAO, COPD, and IAD. What do all of these have in common? A base in allergies. In this episode we are talking about:Calling your vet. Breathing issues are no joke and there are other more serious conditions to rule out.Nutritional support, where to start, what to change from the base anti-inflammatory forage diet.Herbal support - individual herbs to try and my favorite blended pre-made productsHomeopathy - supporting constitutionally, with nosodes, and symptom support Find all the Resource Listed Here: linktr.ee/equineenergymed Audrey is not an MD or DVM and has never implied or claimed to be either. Audrey holds a Doctoral Degree of Traditional Naturopathy and a Masters Degree in Science. She created an evidenced-based anti-inflammatory nutrition program for equine and has successfully helped over 10k horses. This information is not meant to diagnose, prescribe for, treat, or cure, and is not a replacement for your veterinarian. These are my personal interpretations based on my education, skill and clinical experience.

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Today, we're focusing on an often-overlooked peptide called VIP, short for Vasoactive Intestinal Peptide. The name might sound technical, but this peptide plays some important roles in the body. It helps regulate inflammation, supports nerve function, improves blood flow by relaxing blood vessels, and may even have benefits for things like chronic pain, including back pain. Let's get into it. What is VIP? We've talked about VIP before on a previous podcast, but it's been awhile and I'd like to start with the basics as a refresher.  VIP is a 28-amino acid neuropeptide that acts like a signaling molecule in both the central and peripheral nervous systems. Think of it like a chemical messenger that can influence a lot of different body systems. VIP belongs to the glucagon/secretin peptide superfamily, and it's found throughout the body, including your brain, intestines, lungs, and immune cells. Now, what does VIP actually do? Well it does quite a bit. VIP works by binding to specific receptors on cells—called VPAC1 and VPAC2—which trigger a chain reaction inside the body through something known as the cyclic AMP pathway. Once activated:  It relaxes smooth muscles, which helps open up blood vessels (vasodilation) and airways (bronchodilation) It stimulates secretion of water and electrolytes in places like the gut and pancreas—so yes, it helps with digestion too It's a major immune modulator, calming inflammation by regulating immune cell behavior  Neuroprotective role, supporting the survival and adaptability of neurons VIP in Medicine – What's the Buzz? VIP has been studied in a variety of conditions. Inflammatory diseases like rheumatoid arthritis and Crohn's Neurodegenerative conditions like Alzheimer's and Parkinson's Autoimmune diseases like osteoarthritis Respiratory conditions like pulmonary arterial hypertension (PAH), asthma, and chronic obstructive pulmonary disease (COPD) or due to mold toxicity But today, we're zooming in on something more tangible for a lot of people—back pain. VIP and Back Pain – What Do We Know? Let's get into the science here. VIP has recently caught attention for its potential role in intervertebral disc degeneration, which is one of the top causes of chronic low back pain. A 2024 study found that VIP receptors were significantly reduced in degenerated human discs—which is kind of a red flag. When VIP was given to mice for four weeks, researchers saw slowed degeneration, better structural proteins like aggrecan, and overall healthier discs on imaging. Promising, right? But here's the catch—this was a preclinical animal study. We still need human trials to confirm it works outside the lab. VIP and Joint Pain And when it comes to VIP and joint pain, there's a bit more research on VIP and osteoarthritis, especially when the spine is involved. In OA models, VIP was shown to lower pro-inflammatory cytokines—those molecules that contribute to pain and make joints hurt. But here's where it gets complicated: some studies report that VIP accumulation in joints might actually worsen pain. So... it's a bit of a paradox. So what's the takeaway? VIP can be helpful—but its role in pain management seems to depend on how much, where, and what kind of pain we're talking about. VIP in Peptide Therapy – Real-World Use? In peptide clinics—especially those using integrative or regenerative medicine approaches—VIP is sometimes part of treatment protocols for nerve-related pain and inflammation. It's often paired with other peptides like BPC-157 and TB-500. You can find some clinics that list VIP as a go-to for chronic pain, including back pain. But here's the reality check, clinical data is limited, success is anecdotal, it's pricey and results can vary from person to person. So while VIP might help reduce inflammation and slow tissue degeneration, it's not a substitute for tried-and-true pain management peptides like BPC-157. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

In the first episode of our Rare Lung Diseases podcast series, host Saranya Ravindran speaks with James Stoller, Chief of Education and Pulmonary Physician at Cleveland Clinic, about Alpha-1 antitrypsin deficiency, a rare genetic condition that is frequently underdiagnosed. The discussion explores the complexities of Alpha 1, including current challenges in detection, advances in diagnosis and management, and what the future may hold for improving care. Timestamps: 1:20 - Current barriers to timely diagnosis 4:35 - How close are we to identifying all patients with Alpha 1? 5:20 - Role of consumer genomics in alpha detection 6:20 – Targeted testing amongst COPD patients

In this inspiring episode of the She Built It® Podcast, host Melanie Barr speaks with inventor and tech entrepreneur Sharon Samjitsingh, co-founder and CEO of Health Care Originals. Driven by her lifelong struggle with asthma, Sharon shares how her personal story and professional expertise in innovation led her to build life-changing wearable tech that helps people with chronic respiratory diseases. She opens up about the emotional toll of asthma, the importance of first-principles thinking, and her journey as a woman innovating in deep tech. Sharon's story is one of resilience, passion, and purpose—and a reminder that when you can't breathe, nothing else matters.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.

The Good News That Media Doesn't Tell You Before diving into the political chaos, we start with hope: 3D-printed lung tissue that could cure COPD and asthma, revolutionary IVF techniques saving babies from mitochondrial diseases, and breakthrough infant heart transplant procedures expanding donor pools by 20%. Sometimes the best news is the news that reminds us human ingenuity is solving problems we thought impossible. Congressional Chaos & Crypto Drama The Senate passes Trump's $9 billion spending cuts in a nail-biter 51-48 vote, targeting foreign aid and public broadcasting. But the real drama? House Republicans initially blocked crypto bills during "Crypto Week" until Trump personally called holdouts to the Oval Office. We break down the GENIUS Act for stablecoin regulation, Bitcoin hitting $123K, and why regulating an industry you're profiting from might be problematic. The Musk vs. Trump Epstein Files Showdown Elon Musk has gone full chaos mode against Trump over Jeffrey Epstein files, even announcing an "America Party" to prioritize their release. We explore how this billionaire Twitter beef is creating genuine fractures in the MAGA movement and potentially costing Republicans seats in 2026. Immigration Crackdown Reality Check ICE now has access to 79 million Medicaid enrollees' personal data for deportation efforts. We examine the surge in arrests (47% without criminal charges), violent California cannabis farm raids, and the controversial "Alligator Alcatraz" detention center that Democrats and Republicans describe completely differently. International Military Escalation Trump's "Operation Midnight Hammer" strikes on Iranian nuclear facilities, his complete flip on Russia policy with 100% tariff threats, and renewed violence in Syria. Plus, the ongoing Gaza humanitarian crisis and why a 20-year-old American was allegedly killed by Israeli settlers in the West Bank. Research on a Dime: What Is Socialism Actually? We break down the most misunderstood political term in America. Spoiler alert: Those "socialist" Nordic countries? Not actually socialist. Denmark's PM had to literally tell Americans to stop calling them that. We explore real socialism's pros and cons, why Americans already live with tons of "socialist" policies, and what NYC mayoral candidate Zohran Mamdani's democratic socialism experiment might mean for American politics. Domestic Policy Pandemonium Trump freezes $6 billion in education grants, threatens to strip citizenship from political opponents (spoiler: he legally can't), and escalates tariffs on 100+ countries while inflation ticks upward. We also cover the Texas flooding tragedy, church shooting in Kentucky, and why your medical debt might stay on your credit report after all. The Numbers That Matter Bitcoin: $123,165 all-time high ICE arrests: 930 daily (triple the original target) Immigration detention: 60,000 people (20,000 over Congressional funding) Texas flooding: 80+ dead, 41 still missing Gaza casualties: 57,000+ Palestinians killed since October 7, 2023 Purple Political Breakdown cuts through partisan noise to deliver nuanced analysis of the week's biggest political stories. We explain complex policies, decode political theater, and research topics that actually matter all while maintaining our commitment to balanced, fact-based journalism that treats our audience like adults capable of forming their own opinions. Subscribe for weekly episodes breaking down the political stories that shape America, without the partisan spin.Standard Resource Links & RecommendationsThe following organizations and platforms represent valuable resources for balanced political discourse and democratic participation: PODCAST NETWORKALIVE Podcast Network - Check out the ALIVE Network where you can catch a lot of great podcasts like my own, led by amazing Black voices. Link: https://alivepodcastnetwork.com/ CONVERSATION PLATFORMSHeadOn - A platform for contentious yet productive conversations. It's a place for hosted and unguided conversations where you can grow a following and enhance your conversations with AI features. Link: https://app.headon.ai/Living Room Conversations - Building bridges through meaningful dialogue across political divides. Link: https://livingroomconversations.org/ BALANCED NEWS & INFORMATIONOtherWeb - An AI-based platform that filters news without paywalls, clickbait, or junk, helping you access diverse, unbiased content. Link: https://otherweb.com/ VOTING REFORM & DEMOCRACYEqual Vote Coalition & STAR Voting - Advocating for voting methods that ensure every vote counts equally, eliminating wasted votes and strategic voting. Link: https://www.equal.vote/starFuture is Now Coalition (FiNC) - A grassroots movement working to restore democracy through transparency, accountability, and innovative technology while empowering citizens and transforming American political discourse FutureisFutureis. Link: https://futureis.org/ POLITICAL ENGAGEMENTIndependent Center - Resources for independent political thinking and civic engagement. Link: https://www.independentcenter.org/ Get Daily News: Text 844-406-INFO (844-406-4636) with code "purple" to receive quick, unbiased, factual news delivered to your phone every morning via Informed ( https://informed.now) All Links: https://linktr.ee/purplepoliticalbreakdownThe Purple Political Breakdown is committed to fostering productive political dialogue that transcends partisan divides. We believe in the power of conversation, balanced information, and democratic participation to build a stronger society. Our mission: "Political solutions without political bias."Subscribe, rate, and share if you believe in purple politics - where we find common ground in the middle!

On this episode of Vitality Radio, Jared welcomes back naturopathic physician Dr. Lexi Loch from Terry Naturally to uncover two of the most powerful herbs in natural medicine: Boswellia and Curcumin (from Turmeric). While many are familiar with turmeric for inflammation, few realize that Boswellia (also known as frankincense) targets a completely different inflammatory pathway—one that traditional NSAIDs and pain relievers don't touch. Together, these herbs form a potent, well-researched duo for addressing pain and inflammation in the gut, joints, lungs, and beyond. You'll learn about the unique pathway that Boswellia modulates, the advantages of this unique curcumin extract over conventional turmeric extracts, and how combining the two offers faster and longer-lasting support. Whether you're struggling with IBS, asthma, joint pain, or simply want to manage everyday inflammation more naturally, this episode provides evidence-based insight and practical guidance you can trust.Products:Terry Naturally Boswellia & Curcumin ProductsAdditional Information:#524: Maximum Absorption of Nutrients for Energy, Pain, Immune, and Respiratory Challenges with Dr. Lexi LochVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

Dr. Paul will share updates with regard to COPD management including genetics, lung cancer screening and non-prescription treatment options.

#181: Death doesn't have to be a cold, clinical experience tucked away in hospital corners. Yet the word "hospice" still strikes fear in the hearts of so many, often because we fundamentally misunderstand what hospice truly offers.In this profound conversation with Karissa, a veteran hospice nurse with eight years of experience across four different states, we peel back the layers of misconception surrounding end-of-life care. "If death is inevitable, it matters where and when and how," she explains, challenging our cultural tendency to avoid these conversations until it's often too late.What exactly happens when hospice steps in? Far from being just for the imminently dying, hospice provides comprehensive support for both patients and families, sometimes for years rather than days. Karissa walks us through the full spectrum of resources available – from 24/7 nursing support and equipment to spiritual care and family counseling – all covered 100% by Medicare and Medicaid. We explore the telltale signs that it might be time to consider hospice for conditions like CHF, COPD, Alzheimer's, and cancer, and why waiting too long often leads to preventable suffering.Perhaps most beautifully, Karissa describes her role as "midwifery for the dying," drawing a powerful parallel between how we usher life into this world and how we can compassionately guide it out. Whether you're a healthcare provider hesitant to broach this topic with patients, a family member wondering if it's time to consider additional support, or simply someone wanting to understand this inevitable part of the human experience, this episode offers practical wisdom, honest insights, and unexpected moments of lightness in what's typically considered a heavy subject. Listen, share, and join the conversation about making the end of life as meaningful and comfortable as possible.You can now send us a text to ask a question or review the show. We would love to hear from you! Follow me on social: https://www.instagram.com/babbles_nonsense/

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-441 Overview: Explore the evidence behind inspiratory and expiratory strength training to improve sleep quality, reduce daytime fatigue, ease COPD symptoms, and lower blood pressure. This episode offers practical guidance on how you can integrate this simple, affordable intervention to support better breathing and overall health in your patients. Episode resource links: OSA: Journal of Sleep Research. 2024;33(3):e13941. doi:10.1111/jsr.13941. Sleep & Breathing = Schlaf & Atmung. 2022;26(4):1527-1537. doi:10.1007/s11325-021-02536-4. HTN: Journal of Applied Physiology (Bethesda, Md. : 1985). 2020;129(3):449-458. doi:10.1152/japplphysiol.00024.2020. COPD: Chest. 2003;124(4):1357-64. doi:10.1378/chest.124.4.1357. Sleep: Sleep. 2016;39(6):1179-85. doi:10.5665/sleep.5826. Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-441 Overview: Explore the evidence behind inspiratory and expiratory strength training to improve sleep quality, reduce daytime fatigue, ease COPD symptoms, and lower blood pressure. This episode offers practical guidance on how you can integrate this simple, affordable intervention to support better breathing and overall health in your patients. Episode resource links: OSA: Journal of Sleep Research. 2024;33(3):e13941. doi:10.1111/jsr.13941. Sleep & Breathing = Schlaf & Atmung. 2022;26(4):1527-1537. doi:10.1007/s11325-021-02536-4. HTN: Journal of Applied Physiology (Bethesda, Md. : 1985). 2020;129(3):449-458. doi:10.1152/japplphysiol.00024.2020. COPD: Chest. 2003;124(4):1357-64. doi:10.1378/chest.124.4.1357. Sleep: Sleep. 2016;39(6):1179-85. doi:10.5665/sleep.5826. Guest: Robert A. Baldor MD, FAAFP   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

We sit down with three distinguished endocrinologists—Dr. Kashif Latif, Dr. Michael James Haller, and Dr. Kevin Kaiserman—to discuss the last 100 years of innovation in diabetes treatment, from starvation diets to modern insulin therapy.  In this episode, we discuss FDA and non-FDA-approved interventions in medical science. Please do not rely on this podcast for medical advice or as a guide for prescribing. The following were mentioned on the podcast, and you should be aware of their side effects and complete indications as prescribed by the FDA.As with any treatment, it's important to understand the potential adverse reactions with TZIELD. Throughout the TN-10 Study, greater incidences of cytokine release syndrome, serious infections, hypersensitivity reactions, and serum sickness, lymphopenia, and neutropenia were reported in TZIELD-treated patients vs placebo-treated patients. Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache. These are not all the adverse reactions reported with TZIELD. Please see full Important Safety Information and Prescribing Information.AFREZZA can cause serious side effects, including: Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, consult your healthcare clinician.Inhale Study Link 01:25 Early Screening and Universal Screening02:18 Dr. Latif's Journey into Endocrinology04:22 Dr. Haller's Path to Pediatric Endocrinology05:09 Dr. Kaiserman's Career in Diabetes Care05:54 The Importance of EHR in Diabetes Management08:21 Project ECHO: Extending Community Health Outcomes15:39 The Evolution of Insulin Therapy24:22 Revolutionizing Diabetes Care with Inhaled Insulin28:19 Refrigeration and Stability of Insulin28:43 Human Insulin and Genetic Engineering30:04 Inhaled Insulin vs. Insulin Pumps31:33 Inhaled Insulin for Type 2 Diabetics32:28 Challenges in Managing Type 1 Diabetes36:23 Preventing and Delaying Insulin Dependency38:53 The Importance of Early Screening50:14 Future of Type 1 Diabetes TreatmentSupport the show

We love to hear from our listeners. Send us a message. On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations. This episode of the Business of Biotech is brought to you by Ecolab.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Thanks for listening!

Pomegranates are put to the test for weight loss, diabetes, COPD, prostate cancer, osteoarthritis, and rheumatoid arthritis.

Story at-a-glance People managing multiple chronic illnesses are nearly twice as likely to develop depression, even if they've never had mental health issues before, according to a decade-long study Living with both heart disease and diabetes drastically increases your future depression risk, making cardiometabolic combinations among the most dangerous for emotional health outcomes Chronic illnesses like asthma, chronic obstructive pulmonary disease (COPD), liver disease, and bowel disorders sharply increase your risk of depression by overwhelming your body's ability to regulate mood and energy Women with joint and bone issues like arthritis face a higher depression risk than men with the same diagnosis, revealing a serious and often ignored gender vulnerability Depression doesn't just follow disease — it drives it. Left untreated, it speeds up illness progression, weakens your immune system, and increases your chances of hospitalization

Story at-a-glance People managing multiple chronic illnesses are nearly twice as likely to develop depression, even if they've never had mental health issues before, according to a decade-long study Living with both heart disease and diabetes drastically increases your future depression risk, making cardiometabolic combinations among the most dangerous for emotional health outcomes Chronic illnesses like asthma, chronic obstructive pulmonary disease (COPD), liver disease, and bowel disorders sharply increase your risk of depression by overwhelming your body's ability to regulate mood and energy Women with joint and bone issues like arthritis face a higher depression risk than men with the same diagnosis, revealing a serious and often ignored gender vulnerability Depression doesn't just follow disease — it drives it. Left untreated, it speeds up illness progression, weakens your immune system, and increases your chances of hospitalization

Story at-a-glance Research shows perceived stress significantly worsens COPD symptoms, with high stress levels quadrupling the risk of serious flare-ups requiring medical intervention Stress triggers biological changes in COPD patients, increasing inflammation markers and oxidative stress that directly damage lung tissue and impair breathing People with COPD who experience high stress levels report greater death anxiety, especially women, unemployed individuals and those lacking education about their condition Understanding your condition and building confidence in managing symptoms (self-efficacy) significantly reduces both stress levels and physical complications of COPD Simple interventions like focused breathing, symptom tracking and establishing daily routines help interrupt the stress-symptom cycle and improve quality of life